Home

Timothy Rolph

CIK 1779479 · Chief Scientific Officer · last filed 2025-12-09

Timothy Rolph is a Chief Scientific Officer who has filed 55 SEC Form 4 insider transactions across 1 company since 2019. The most recent filing, for AKRO, was dated Dec 9, 2025. Across all open-market trades the lifetime net is −$19.6M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

55

Lifetime Open-Market Net

-$19.56M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Akero Therapeutics, Inc. (AKRO) Delisted Chief Scientific Officer 0 $54.65 $0 -$19.56M 47 2025-12-09

Recent Filings

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-12-09 Akero Therapeutics, Inc. (AKRO) Delisted Disp (D) −282,149 $0 EDGAR
2025-11-28 Akero Therapeutics, Inc. (AKRO) Delisted Exer (M) +152,678 $624.1K EDGAR
2025-11-19 Akero Therapeutics, Inc. (AKRO) Delisted Gift (G) −37,100 $0 EDGAR
2025-10-09 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$221.6K EDGAR
2025-10-07 Akero Therapeutics, Inc. (AKRO) Delisted Notice (144) −56,369 -$2.60M EDGAR
2025-09-12 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −553 -$23.8K EDGAR
2025-09-10 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$362.4K EDGAR
2025-08-07 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$352.7K EDGAR
2025-07-09 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$375.0K EDGAR
2025-07-07 Akero Therapeutics, Inc. (AKRO) Delisted Notice (144) −56,250 -$2.92M EDGAR
Showing 1–10 of 55
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.